The agreement is open ended and non-exclusive, the company said in an announcement to the stock exchange.
DCC is a service provider to healthcare and mail order companies and it has an enviable client list, which includes Merck, GSK, Healthspan and Vitabiotics.
“Securing a licensing agreement for Chewitab with the UK's largest healthcare contract supplier so soon since the IPO of the company demonstrates the strength of our business model and validates the efficacy of our technology,” chief executive Nigel Theobald said.
“The interest being shown by a number of global healthcare companies in our chewable and soluble products is being fueled by healthcare organisations striving to find ways to extend their product life cycles.
“This is creating growing demand for more innovative delivery systems and superior product performance and Chewitab provides a solution to this challenge.
“DCC Health & Beauty Solutions have an outstanding track record of exploiting markets with high performing products and we look forward to exploring other products ideas with them.”
Chewitab is Oxford Nutrascience's proprietary technology used in chewable tablets.
Its product produces a light crunch when bitten and dissolves quickly in the mouth resulting in a soft pleasant feeling with no grittiness and can be taken without water.
This key differentiator makes Chewitabs a highly convenient delivery system and particularly well suited for over-the-counter medicines such as analgesics, allergy treatments, digestive aids and medicines for the elderly as well as vitamins and supplements.
DCC Health & Beauty Solutions is part of DCC plc, a business support services group listed on the Irish and London Stock Exchanges with revenues of €6.7 billion.
Oxford Nutrascience listed on AIM back in February with a market capitalisation of £8.1 million. It raised £1.1 million as part of the float.